ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA, a Swiss biotechnology company focused on pyrrolobenzodiazepine-based antibody-drug conjugates (ADCs), furnished this Form 6-K for June 2021. The filing supplements and updates the risk factors in its Form 20-F for the year ended December 31, 2020.
On April 23, 2021, the FDA granted accelerated approval to Zynlonta (loncastuximab tesirine-lpyl) for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including specified forms of diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
Financial position, financing and liquidity
| Metric | Reported information |
|---|---|
| Accumulated losses | USD 746.4 million as of March 31, 2021 |
| Cash and cash equivalents | USD 383.1 million as of March 31, 2021 |
| Convertible loans outstanding | USD 115.0 million as of the filing date |
| Second financing tranche | USD 50.0 million received May 17, 2021; corresponding senior secured convertible notes issued |
| Nominal interest rate | 5.95% per annum, plus a 2.0% exit charge on principal repaid or converted |
| 2020 non-cash derivative charge | USD 23.4 million related to the first tranche’s embedded conversion feature |
| Liquidity outlook | Management stated that available resources were sufficient to fund projected operating requirements for at least the next twelve months as of March 31, 2021 |
The filing does not provide current-period revenue, net loss, operating cash flow, free cash flow, gross margin or operating margin figures. Management expects continued net losses as it funds Zynlonta development and commercialization, clinical programs, manufacturing and research activities.
Material changes versus the prior comparable period
- Zynlonta received FDA accelerated approval in April 2021, shifting the company toward commercial launch and post-approval obligations.
- The company received the second USD 50.0 million tranche under the Deerfield Facility Agreement in May 2021, increasing total convertible loans outstanding to USD 115.0 million.
- The additional convertible debt is expected to increase fair-value volatility and non-cash interest expense in future periods.
- The company disclosed that it may lose foreign private issuer status as of June 30, 2021, which could require compliance with the more extensive U.S. domestic issuer reporting regime beginning January 1, 2022.
Guidance, outlook, risks and unusual items
Management expects substantial ongoing spending and continuing losses and cannot predict when profitability will be achieved or sustained. Although it believes current liquidity covers at least twelve months of projected requirements, it has no committed external source of additional funds and may need further equity, convertible debt, credit facilities or collaboration financing.
- Debt restrictions: The Facility Agreement requires at least USD 50.0 million to be retained in deposit and securities accounts at each fiscal quarter-end and restricts dividends, liens, asset dispositions, additional indebtedness, investments and certain corporate transactions. The debt is secured by substantially all personal property, including intellectual property and equity interests in certain subsidiaries and joint ventures.
- Debt service and dilution: The notes require cash interest and eventual repayment or conversion. The first USD 65.0 million tranche is convertible at USD 24.70 per share and the second USD 50.0 million tranche at USD 28.07 per share, subject to adjustment. Conversion could materially dilute existing shareholders.
- Accelerated approval obligations: Zynlonta requires confirmatory clinical testing and other post-marketing commitments, including deferred pediatric and hepatic-impairment trials. Failure to verify clinical benefit or comply with requirements could result in withdrawal of approval.
- Clinical and safety risks: Cami clinical trials previously experienced partial clinical holds associated with Guillain-Barré syndrome and polyradiculopathy. Zynlonta labeling includes warnings for effusion and edema, myelosuppression, infections, cutaneous reactions and embryo-fetal toxicity.
- Manufacturing and supply: The company relies heavily on third-party manufacturers and service providers for complex ADC components. Manufacturing deviations, supply interruptions, quality failures or inability to scale production could delay trials or impair commercialization.
- Commercialization: Zynlonta market acceptance, physician adoption, payer coverage, reimbursement and pricing remain uncertain, and the company has limited experience as a commercial-stage organization.
- Capital requirements: Additional financing may be unavailable or available only on unfavorable or dilutive terms. Failure to obtain financing could require reductions or delays in research, development and commercialization.
- COVID-19 and operational risks: The pandemic could disrupt clinical enrollment, manufacturing, supply chains, regulatory activities and commercialization, although the ultimate financial impact was not reasonably predictable at the filing date.
- Other risks: The filing highlights dependence on PBD technology, competition, intellectual property disputes, third-party collaborations, data privacy and cybersecurity, foreign exchange, tax matters, product liability and internal-control risks.
Most important facts for investors to verify
- Current Zynlonta launch performance, revenue, gross-to-net adjustments, payer coverage and commercial cash generation.
- Status, enrollment, timing and results of Zynlonta confirmatory and other post-marketing trials, and the potential effect on accelerated approval.
- Cash burn, quarterly operating cash flow, remaining liquidity and the timing and terms of any additional financing.
- Outstanding principal, interest, conversion terms, collateral, covenant compliance and potential dilution under the Deerfield Facility Agreement.
- Whether ADC Therapeutics retained foreign private issuer status after June 30, 2021 and any resulting reporting or compliance changes.
- Regulatory and safety developments for Cami and other product candidates, including any new clinical holds or serious adverse events.
- Manufacturing capacity, product supply reliability and dependence on single or limited third-party manufacturers.